- Home
- GWH vs ACRV Comparison
GWH vs ACRV Comparison
Compare GWH & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GWH | ACRV |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 240 | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8M | 47.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | GWH | ACRV |
|---|---|---|
| Price | $1.30 | $1.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.50 | ★ $13.00 |
| AVG Volume (30 Days) | 464.7K | ★ 948.4K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $276.44 | N/A |
| Revenue Next Year | $571.19 | $805.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $1.05 |
| 52 Week High | $13.87 | $5.65 |
Technical Indicators
Market Signals| Indicator | GWH | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 36.70 | 48.83 |
| Support Level | $1.22 | $1.49 |
| Resistance Level | $1.80 | $1.86 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 18.37 | 55.06 |
Price Performance
Historical ComparisonAbout GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.